Alseres Pharmaceuticals Competitors

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and Rosetta Genomics, as provided by MarketBeat.

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, indicating that its share price is 539% more volatile than the S&P 500.

Profitability

This table compares Alseres Pharmaceuticals and Rosetta Genomics' net margins, return on equity and return on assets.

Summary

Rosetta Genomics beats Alseres Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and MetaStat (OTCMKTS:MTST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and MetaStat's revenue, earnings per share (EPS) and valuation.

Alseres Pharmaceuticals has higher earnings, but lower revenue than MetaStat.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and MetaStat, as provided by MarketBeat.

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, MetaStat has a beta of -4.21, indicating that its share price is 521% less volatile than the S&P 500.

Profitability

This table compares Alseres Pharmaceuticals and MetaStat's net margins, return on equity and return on assets.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Orexigen Therapeutics' revenue, earnings per share (EPS) and valuation.

Alseres Pharmaceuticals has higher earnings, but lower revenue than Orexigen Therapeutics.

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, indicating that its share price is 398% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and Orexigen Therapeutics, as provided by MarketBeat.

Profitability

This table compares Alseres Pharmaceuticals and Orexigen Therapeutics' net margins, return on equity and return on assets.

Summary

Orexigen Therapeutics beats Alseres Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and AXM Pharma (OTCMKTS:AXMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and AXM Pharma's revenue, earnings per share (EPS) and valuation.

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, AXM Pharma has a beta of -52.62, indicating that its share price is 5,362% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and AXM Pharma, as provided by MarketBeat.com.

Profitability

This table compares Alseres Pharmaceuticals and AXM Pharma's net margins, return on equity and return on assets.

Summary

Alseres Pharmaceuticals beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Bohai Pharmaceuticals Group (OTCMKTS:BOPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Bohai Pharmaceuticals Group's revenue, earnings per share (EPS) and valuation.

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Bohai Pharmaceuticals Group has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and Bohai Pharmaceuticals Group, as provided by MarketBeat.com.

Profitability

This table compares Alseres Pharmaceuticals and Bohai Pharmaceuticals Group's net margins, return on equity and return on assets.

Summary

Bohai Pharmaceuticals Group beats Alseres Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Immune Therapeutics' revenue, earnings per share (EPS) and valuation.

Alseres Pharmaceuticals has higher earnings, but lower revenue than Immune Therapeutics.

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. 8.9% of Alseres Pharmaceuticals shares are owned by insiders. Comparatively, 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and Immune Therapeutics, as provided by MarketBeat.com.

Profitability

This table compares Alseres Pharmaceuticals and Immune Therapeutics' net margins, return on equity and return on assets.

Summary

Immune Therapeutics beats Alseres Pharmaceuticals on 5 of the 6 factors compared between the two stocks.